Upgraded Doximity to a buy rating due to recent share price pullback, stronger engagement metrics, and deeper client relationships, creating a compelling entry point. DOCS reported 20% y/y revenue gro...

In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne...

Five stocks have strong momentum for January. These are: DOCS, LUV, ALK, DBX, PARRA.

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most.

Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-...

Doximity (DOCS) closed the most recent trading day at $58.18, moving +0.61% from the previous trading session.

Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.

Doximity stock jumped over 34% following its most recent earnings report on Nov. 11. Now, shares are nearing a buy point.

Stephens initiated coverage of Doximity with an Equal Weight rating and $55 price target. Doximity runs the "leading digital platform for doctors" and is executing on multiple avenues of growth, thoug...

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its State of Telemedicine Report, showing that 83% of physician...

The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth.

Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financ...

Five Health & Fitness stocks have strong growth potential for 2025. These are GRMN, SFM, DOCS, PLNT and PTON.

Mizuho initiated coverage of Doximity with a Neutral rating and $55 price target. The company has witnessed some volatility in quarterly top-line growth over the past few years due to timing of pharma...

Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year.

The post-IPO narrative surrounding footwear icon Dr Martens PLC (LSE:DOCS) has been so overwhelmingly negative that it's easy to glance over the green shoots of optimism emerging from the business. Wh...

Dr Martens PLC (LSE:DOCS)'s double-digit revenue decline and pre-tax loss in the first half wasn't as bad as it seems, if the market's reaction is anything to go by. Shares in the shoe brand, which ha...

Dr Martens PLC (LSE:DOCS) had another unflattering trading performance in the first half of its financial year, with revenues declining 18% year-on-year to £325 million, in line with expectations. The...

Dr Martens PLC (LSE:DOCS)'s first half results on Thursday, 28 November will likely be more about its outlook as a decline in sales and swing to loss are expected. According to Deutsche Bank analysts,...

DOCS, PI and INOD are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.